The HHS wants to move oversight of the controversial drug discount program to the CMS, which has a more aggressive history ...

From relentless claim denials and payer pressures to policy debates around prior authorization and the 340B program, this mid-year briefing unpacks the six essential stories every revenue cycle leader ...

A federal judge ruled that the government did not violate the law in a dispute with J&J over the 340B drug discount program.

A federal court denied Johnson & Johnson's motion to implement a 340B drug rebate model, siding with HHS and hospitals who ...

Moderna disclosed that a study of 56,000 volunteers older than 50 found its new mRNA flu vaccine was more effective than an ...

The industry is awaiting guidance on a rebate approach to the contentious drug discount program for hospitals and aiming for tighter oversight.

The AHA June 27 filed an amicus brief in the U.S. District Court for the Middle District of Tennessee that defends the ...

The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie ...

AbbVie Inc. and other drug makers lost a bid to block a Tennessee law regulating contracts between pharmaceutical companies ...

Oklahoma lawmakers passed HB 2048 to protect the 340B Drug Pricing Program, overriding a veto amid growing pressure from pharmaceutical interests.

340B was created to help serve patients with limited options, but today it rewards scale and billing volume. Congress and federal regulators must realign the provision with its original purpose.